The target trial emulation study suggests rigid risk thresholds aren’t needed to steer statin use in this group.

Findings of reduced risks for mortality and major CVD suggest consideration of statins in all adults with type 2 diabetes, even in those with low short-term predicted CVD risk.

Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. doi: 10.1056/NEJMoa1600176. Yusuf S, HOPE-3 Investigators. Abstract 401-19. Effects of combined lipid ...

Dr Salim Yusuf, president of the World Heart Federation, was careful to note that trials lasting 5 to 6 years, such as HOPE-3, often underestimate the benefits of prevention. Over longer periods of ...

For adults with type 2 diabetes (T2DM), statin initiation is associated with reductions in all-cause mortality and major ...

nurse assessing stroke victim 44% drop in stroke for those with intermediate CVD risk receiving candesartan/HCTZ, rosuvastatin (HealthDay News) — For patients with intermediate risk of cardiovascular ...

Roughly half of patients who present to the hospital with their first MI would not have been eligible for statin therapy based on two popular risk-assessment tools had they been seen in a cardiology ...

Please provide your email address to receive an email when new articles are posted on . Using visualized coronary calcium scoring independently reduced plaque progression among patients at ...

A long list of Lynda Hollander's paternal relatives had heart disease, and several had undergone major surgeries. So when she hit her mid-50s and saw her cholesterol levels creeping up after menopause ...